MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

This study has been completed.
Sponsor:
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00094653
First received: October 21, 2004
Last updated: June 29, 2011
Last verified: June 2011
Results First Received: April 22, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator);   Primary Purpose: Treatment
Conditions: Melanoma
Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody
Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Of the 1783 participants who enrolled and were screened for study participation, a total of 676 subjects were randomized.

Reporting Groups
  Description
Ipilimumab Plus gp100 Ipilimumab was administered at a dosage of 3 mg/kg as an intravenous (IV) infusion administered over 90 minutes every 3 weeks for a total of 4 doses, together with gp100. Gp100 consisted of 2 separate peptide components: Peptide A, a peptide with sequence YLEPGPVTV (gp100:280-288[288V]) and Peptide B, a peptide with the sequence IMDQVPFSV (gp100:209-217[210M]). Each peptide was prepared with Montanide ISA-51. One dose of gp100 consisted of the administration of Peptide A, at a dosage of 2 mL or 1 mg, and Peptide B, at a dosage of 2 mL or 1 mg. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.
Ipilimumab Monotherapy Ipilimumab was administered at a dosage of 3 mg/kg as an intravenous (IV) infusion administered over 90 minutes every 3 weeks for a total of 4 doses, together with matching vaccine placebo. The vaccine placebo consisted of sterile 0.9% sodium chloride. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.
gp100 Gp100 consisted of 2 separate peptide components: Peptide A, a peptide with sequence YLEPGPVTV (gp100:280-288[288V]) and Peptide B, a peptide with the sequence IMDQVPFSV (gp100:209-217[210M]). Each peptide was prepared with Montanide ISA-51. One dose of gp100 consisted of the administration of Peptide A, at a dosage of 2 mL or 1 mg, and Peptide B, at a dosage of 2 mL or 1 mg. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.

Participant Flow:   Overall Study
    Ipilimumab Plus gp100     Ipilimumab Monotherapy     gp100  
STARTED     403     137     136  
Treated     381     131     131  
COMPLETED     82     31     10  
NOT COMPLETED     321     106     126  
Death                 306                 100                 119  
Subject Withdrew Consent                 10                 2                 3  
Not specified                 2                 2                 2  
Lost to Follow-up                 3                 2                 1  
Protocol Violation                 0                 0                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Ipilimumab Plus gp100 Ipilimumab was administered at a dosage of 3 mg/kg as an intravenous (IV) infusion administered over 90 minutes every 3 weeks for a total of 4 doses, together with gp100. Gp100 consisted of 2 separate peptide components: Peptide A, a peptide with sequence YLEPGPVTV (gp100:280-288[288V]) and Peptide B, a peptide with the sequence IMDQVPFSV (gp100:209-217[210M]). Each peptide was prepared with Montanide ISA-51. One dose of gp100 consisted of the administration of Peptide A, at a dosage of 2 mL or 1 mg, and Peptide B, at a dosage of 2 mL or 1 mg. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.
Ipilimumab Monotherapy Ipilimumab was administered at a dosage of 3 mg/kg as an intravenous (IV) infusion administered over 90 minutes every 3 weeks for a total of 4 doses, together with matching vaccine placebo. The vaccine placebo consisted of sterile 0.9% sodium chloride. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.
gp100 Gp100 consisted of 2 separate peptide components: Peptide A, a peptide with sequence YLEPGPVTV (gp100:280-288[288V]) and Peptide B, a peptide with the sequence IMDQVPFSV (gp100:209-217[210M]). Each peptide was prepared with Montanide ISA-51. One dose of gp100 consisted of the administration of Peptide A, at a dosage of 2 mL or 1 mg, and Peptide B, at a dosage of 2 mL or 1 mg. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.
Total Total of all reporting groups

Baseline Measures
    Ipilimumab Plus gp100     Ipilimumab Monotherapy     gp100     Total  
Number of Participants  
[units: participants]
  403     137     136     676  
Age  
[units: years]
Mean ( Full Range )
  55.6  
  ( 24 to 84 )  
  56.8  
  ( 19 to 88 )  
  57.4  
  ( 23 to 90 )  
  56.2  
  ( 19 to 90 )  
Age, Customized  
[units: participants]
       
< 65 years     291     95     94     480  
>=65 years     112     42     42     196  
Gender  
[units: participants]
       
Female     156     56     63     275  
Male     247     81     73     401  
Race/Ethnicity, Customized  
[units: Participants]
       
White     380     129     129     638  
Black     3     1     1     5  
Hispanic     18     7     5     30  
Other     2     0     1     3  
Duration of Melanoma [1]
[units: years]
Mean ( Full Range )
  5.09  
  ( 0.2 to 38.9 )  
  4.34  
  ( -0.0 to 35.9 )  
  5.65  
  ( 0.3 to 31.2 )  
  5.05  
  ( -0.0 to 38.9 )  
Melanoma Stage [2]
[units: Participants]
       
M0     5     1     4     10  
M1a     37     14     11     62  
M1b     76     22     23     121  
M1c     285     100     98     483  
Prior Interleukin-2 Therapy  
[units: Participants]
       
No     314     105     103     522  
Yes     89     32     33     154  
Lactate Dehydrogenase [3]
[units: Participants]
       
>upper limit of normal (ULN)     149     53     52     254  
<=ULN     252     84     81     417  
unknown     2     0     3     5  
[1] Duration of melanoma is the number of years from date of initial diagnosis to the date of randomization. The randomization of 1 participant in the ipilumumab monotherapy cohort was prior to the initial diagnostic date. Data for 2 participants in the ipilimumab + gp100 cohort were missing.
[2] The "M" in the TNM (tumor, node, metastasis) system refers to distant metastases—whether, and how far, the cancer has spread outside the original site. M0: There is no evidence that the cancer has spread beyond the original site. M1: The cancer has spread beyond the original site. M1a: The cancer has spread to other areas of skin, underneath the epidermis to the dermis (subcutaneous), or to lymph node(s). M1b: The cancer has spread to the lung(s) only. M1c: The cancer has spread to other organs and/or locations in the body with or without elevated LDH.
[3] Upper limit of normal (ULN) was 250 U/L for most assessments (some variation caused by tests performed at local laboratories).



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone   [ Time Frame: From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks) ]

2.  Secondary:   Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 Monotherapy Versus gp100 Melanoma Peptide Vaccine Alone and MDX-010 in Combination With gp100 Melanoma Peptide Vaccine Versus MDX-010 Monotherapy   [ Time Frame: From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks) ]

3.  Secondary:   12-, 18-, and 24-Month Survival Rates   [ Time Frame: Month 12, Month 18, Month 24 ]

4.  Secondary:   Progression Free Survival (PFS)   [ Time Frame: From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks) ]

5.  Secondary:   Percentage of Participants With Progression Free Survival (PFS) at Week 12 and Week 24   [ Time Frame: Week 12, Week 24 ]

6.  Secondary:   Time to Progression (TTP)   [ Time Frame: from time of randomization to date of PD or death due to PD (end of the study was defined as the time at which 481 deaths were observed [264 weeks]) ]

7.  Secondary:   Best Overall Response (BOR): Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressed Disease (PD)   [ Time Frame: BOR was determined between Weeks 12 and Week 24 confirmation at least 4 weeks later at Cycle 1. ]

8.  Secondary:   Determination of Best Overall Response Rate (BORR)   [ Time Frame: Up to week 24 ]

9.  Secondary:   Time to Response   [ Time Frame: From randomization until the end of the study, which was defined as the time at which 481 deaths were observed (264 weeks) ]

10.  Secondary:   Duration of Response   [ Time Frame: from time of initial drug administration to date of PD or death due to PD (the end of the study was defined as the time at which 481 deaths were observed [264 weeks]) ]

11.  Secondary:   Disease Control Rate (DCR)   [ Time Frame: Up to week 24 ]

12.  Secondary:   Delayed Response (Response Beyond Week 24)   [ Time Frame: from Week 24 to end of study (the end of the study was defined as the time at which 481 deaths were observed [264 weeks]) ]

13.  Secondary:   Change From Baseline in Health-Related Quality of Life (QOL) as Measured by the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Instrument at Week 12   [ Time Frame: Baseline (Day 1, Cycle1), Week 12 ]

14.  Secondary:   Percentage of Participants With On-Study Adverse Events (AEs) and AEs With an Outcome of Death   [ Time Frame: On-study adverse events include all AEs reported between the first dose and 70 days after the last dose of study therapy (end of the study was defined as the time at which 481 deaths were observed [264 weeks]). ]

15.  Secondary:   Percentage of Participants With Immune-Related Adverse Events (irAEs)   [ Time Frame: On-study adverse events include all AEs reported between the first dose and 70 days after the last dose of study therapy (end of the study was defined as the time at which 481 deaths were observed [264 weeks]). ]

16.  Secondary:   Percentage of Participants With Worst On-Study Hematological Abnormalities   [ Time Frame: On-study laboratory results are results reported after the first dose date and within 70 days of last dose of study therapy (end of the study was defined as the time at which 481 deaths were observed [264 weeks]). ]

17.  Secondary:   Percentage of Participants With Worst On-Study Liver Abnormalities   [ Time Frame: On-study adverse events include all AEs reported between the first dose and 70 days after the last dose of study therapy (end of the study was defined as the time at which 481 deaths were observed [264 weeks]). ]

18.  Secondary:   Percentage of Participants With Worst On-Study Renal Abnormalities   [ Time Frame: On-study adverse events include all AEs reported between the first dose and 70 days after the last dose of study therapy (end of the study was defined as the time at which 481 deaths were observed [264 weeks]). ]

19.  Secondary:   Clinically Meaningful Changes in Vital Signs and Physical Examinations   [ Time Frame: vital signs and physical examination were evaluated at screening and at Weeks 1, 4, 7, 10, 12, 16, 20, 24, 28, 36, and every 3 months thereafter ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame No text entered.
Additional Description No text entered.

Frequency Threshold
Threshold above which other adverse events are reported   5%  

Reporting Groups
  Description
Ipilimumab Monotherapy Ipilimumab was administered at a dosage of 3 mg/kg as an intravenous (IV) infusion administered over 90 minutes every 3 weeks for a total of 4 doses, together with matching vaccine placebo. The vaccine placebo consisted of sterile 0.9% sodium chloride. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.
Ipilimumab Plus gp100 Ipilimumab was administered at a dosage of 3 mg/kg as an intravenous (IV) infusion administered over 90 minutes every 3 weeks for a total of 4 doses, together with gp100. Gp100 consisted of 2 separate peptide components: Peptide A, a peptide with sequence YLEPGPVTV (gp100:280-288[288V]) and Peptide B, a peptide with the sequence IMDQVPFSV (gp100:209-217[210M]). Each peptide was prepared with Montanide ISA-51. One dose of gp100 consisted of the administration of Peptide A, at a dosage of 2 mL or 1 mg, and Peptide B, at a dosage of 2 mL or 1 mg. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.
gp100 Gp100 consisted of 2 separate peptide components: Peptide A, a peptide with sequence YLEPGPVTV (gp100:280-288[288V]) and Peptide B, a peptide with the sequence IMDQVPFSV (gp100:209-217[210M]). Each peptide was prepared with Montanide ISA-51. One dose of gp100 consisted of the administration of Peptide A, at a dosage of 2 mL or 1 mg, and Peptide B, at a dosage of 2 mL or 1 mg. After Week 12, subjects who met re-induction criteria could receive further cycles of their randomized study therapy.

Other Adverse Events
    Ipilimumab Monotherapy     Ipilimumab Plus gp100     gp100  
Total, other (not including serious) adverse events        
# participants affected / at risk     124/131     362/380     124/132  
Blood and lymphatic system disorders        
ANAEMIA † 1      
# participants affected / at risk     14/131 (10.69%)     36/380 (9.47%)     22/132 (16.67%)  
Gastrointestinal disorders        
ABDOMINAL DISTENSION † 1      
# participants affected / at risk     0/131 (0.00%)     13/380 (3.42%)     9/132 (6.82%)  
ABDOMINAL PAIN † 1      
# participants affected / at risk     20/131 (15.27%)     64/380 (16.84%)     18/132 (13.64%)  
ABDOMINAL PAIN UPPER † 1      
# participants affected / at risk     7/131 (5.34%)     17/380 (4.47%)     11/132 (8.33%)  
CONSTIPATION † 1      
# participants affected / at risk     27/131 (20.61%)     79/380 (20.79%)     34/132 (25.76%)  
DIARRHOEA † 1      
# participants affected / at risk     41/131 (31.30%)     142/380 (37.37%)     26/132 (19.70%)  
DYSPEPSIA † 1      
# participants affected / at risk     2/131 (1.53%)     14/380 (3.68%)     10/132 (7.58%)  
FLATULENCE † 1      
# participants affected / at risk     3/131 (2.29%)     9/380 (2.37%)     8/132 (6.06%)  
NAUSEA † 1      
# participants affected / at risk     44/131 (33.59%)     127/380 (33.42%)     49/132 (37.12%)  
VOMITING † 1      
# participants affected / at risk     30/131 (22.90%)     71/380 (18.68%)     27/132 (20.45%)  
General disorders        
ADVERSE EVENT † 1      
# participants affected / at risk     4/131 (3.05%)     22/380 (5.79%)     5/132 (3.79%)  
ASTHENIA † 1      
# participants affected / at risk     6/131 (4.58%)     37/380 (9.74%)     17/132 (12.88%)  
CHILLS † 1      
# participants affected / at risk     9/131 (6.87%)     23/380 (6.05%)     7/132 (5.30%)  
FATIGUE † 1      
# participants affected / at risk     55/131 (41.98%)     137/380 (36.05%)     41/132 (31.06%)  
INFLUENZA LIKE ILLNESS † 1      
# participants affected / at risk     7/131 (5.34%)     20/380 (5.26%)     3/132 (2.27%)  
INJECTION SITE ERYTHEMA † 1      
# participants affected / at risk     1/131 (0.76%)     26/380 (6.84%)     5/132 (3.79%)  
INJECTION SITE INDURATION † 1      
# participants affected / at risk     0/131 (0.00%)     25/380 (6.58%)     4/132 (3.03%)  
INJECTION SITE PAIN † 1      
# participants affected / at risk     2/131 (1.53%)     25/380 (6.58%)     13/132 (9.85%)  
INJECTION SITE REACTION † 1      
# participants affected / at risk     2/131 (1.53%)     109/380 (28.68%)     26/132 (19.70%)  
OEDEMA PERIPHERAL † 1      
# participants affected / at risk     12/131 (9.16%)     47/380 (12.37%)     22/132 (16.67%)  
PAIN † 1      
# participants affected / at risk     6/131 (4.58%)     23/380 (6.05%)     15/132 (11.36%)  
PYREXIA † 1      
# participants affected / at risk     15/131 (11.45%)     74/380 (19.47%)     23/132 (17.42%)  
Infections and infestations        
URINARY TRACT INFECTION † 1      
# participants affected / at risk     8/131 (6.11%)     8/380 (2.11%)     4/132 (3.03%)  
Investigations        
WEIGHT DECREASED † 1      
# participants affected / at risk     8/131 (6.11%)     33/380 (8.68%)     12/132 (9.09%)  
Metabolism and nutrition disorders        
DECREASED APPETITE † 1      
# participants affected / at risk     33/131 (25.19%)     85/380 (22.37%)     29/132 (21.97%)  
Musculoskeletal and connective tissue disorders        
ARTHRALGIA † 1      
# participants affected / at risk     12/131 (9.16%)     30/380 (7.89%)     14/132 (10.61%)  
BACK PAIN † 1      
# participants affected / at risk     9/131 (6.87%)     32/380 (8.42%)     16/132 (12.12%)  
MUSCULOSKELETAL CHEST PAIN † 1      
# participants affected / at risk     7/131 (5.34%)     7/380 (1.84%)     2/132 (1.52%)  
MUSCULOSKELETAL PAIN † 1      
# participants affected / at risk     5/131 (3.82%)     30/380 (7.89%)     10/132 (7.58%)  
MYALGIA † 1      
# participants affected / at risk     8/131 (6.11%)     28/380 (7.37%)     4/132 (3.03%)  
PAIN IN EXTREMITY † 1      
# participants affected / at risk     9/131 (6.87%)     51/380 (13.42%)     19/132 (14.39%)  
Nervous system disorders        
DIZZINESS † 1      
# participants affected / at risk     5/131 (3.82%)     27/380 (7.11%)     13/132 (9.85%)  
HEADACHE † 1      
# participants affected / at risk     19/131 (14.50%)     64/380 (16.84%)     18/132 (13.64%)  
Psychiatric disorders        
ANXIETY † 1      
# participants affected / at risk     5/131 (3.82%)     31/380 (8.16%)     9/132 (6.82%)  
INSOMNIA † 1      
# participants affected / at risk     16/131 (12.21%)     33/380 (8.68%)     15/132 (11.36%)  
Respiratory, thoracic and mediastinal disorders        
COUGH † 1      
# participants affected / at risk     21/131 (16.03%)     55/380 (14.47%)     17/132 (12.88%)  
DYSPNOEA † 1      
# participants affected / at risk     16/131 (12.21%)     45/380 (11.84%)     20/132 (15.15%)  
Skin and subcutaneous tissue disorders        
ERYTHEMA † 1      
# participants affected / at risk     10/131 (7.63%)     26/380 (6.84%)     7/132 (5.30%)  
HYPERHIDROSIS † 1      
# participants affected / at risk     6/131 (4.58%)     14/380 (3.68%)     12/132 (9.09%)  
PRURITUS † 1      
# participants affected / at risk     39/131 (29.77%)     79/380 (20.79%)     14/132 (10.61%)  
RASH † 1      
# participants affected / at risk     29/131 (22.14%)     78/380 (20.53%)     9/132 (6.82%)  
Vascular disorders        
HOT FLUSH † 1      
# participants affected / at risk     6/131 (4.58%)     8/380 (2.11%)     8/132 (6.06%)  
HYPOTENSION † 1      
# participants affected / at risk     8/131 (6.11%)     12/380 (3.16%)     4/132 (3.03%)  
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 12.1



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: BMS Study Director
Organization: Bristol-Myers Squibb
e-mail: Clinical.Trials@bms.com


No publications provided by Bristol-Myers Squibb

Publications automatically indexed to this study:


Responsible Party: Study Director, Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00094653     History of Changes
Other Study ID Numbers: MDX010-20, CA184-002
Study First Received: October 21, 2004
Results First Received: April 22, 2011
Last Updated: June 29, 2011
Health Authority: United States: Food and Drug Administration